MedTrace Logo

Perception of Health Promotion Messages

NCT07042789 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 763

Last updated 2025-06-29

No results posted yet for this study

Summary

The specific aims of this study are:

1. To compare the perceived message effectiveness (PME) of AI-generated vaping prevention materials with existing traditionally generated (typically by a health authority) prevention materials in a sample of young people. This aim addresses the gap in understanding whether AI can match or exceed the effectiveness of traditional prevention materials in changing youth perceptions and intentions of vaping.
2. To examine the impact of ad labelling (AI-generated, AI-generated with health authority endorsement, and unlabelled) on the PME of vaping prevention messages. Given the novelty of AI in this context, understanding the influence of transparency about message origin and endorsements on message reception is critical.

Conditions

  • Perception of Vaping

Interventions

OTHER

Material source: AI generated ads vs existing ads by health agency

Each participant evaluated 50 ads in random order, of which 25 were AI-generated through youth co-design process, and 25 were existing ads from official health agencies.

OTHER

source labelling conditions: control condition, AI condition, health agency condition, combined condition

Participants were randomly assigned to one of four source labelling conditions: (1) Control (ads presented without any source labelling), (2) AI condition (ads labelled with the text "Made with AI"), (3) Health agency condition (ads labelled with the text "Made by the World Health Organization (WHO)"), and (4) Combined condition (ads labelled with the text "Made with AI, by the World Health Organization (WHO)").

Sponsors & Collaborators

  • The University of Queensland

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
FACTORIAL

Eligibility

Min Age
16 Years
Max Age
25 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-08-24
Primary Completion
2024-11-20
Completion
2024-11-20

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07042789 on ClinicalTrials.gov